Table 1 Baseline characteristics by treatment group
Characteristic | Treatment group | All | ||
|---|---|---|---|---|
Old policy (n = 146) | New policy (n = 63) | P | (n = 209) | |
Age, mean (SD), yr | 49.20 (11.73) | 41.94 (12.03) | < 0.001 | 47.01 (12.26) |
Sex (female), no. (%) | 122 (83.6%) | 52 (82.5%) | 0.856 | 174 (83.3%) |
Baseline MHD, median (IQR) d/mo | 15 (11–21) | 12 (9–16) | 0.011 | 14 (10–20) |
Baseline MMD, median (IQR) d/mo | 13 (9–16) | 11 (7–13) | 0.011 | 12 (9–15) |
Number of previous preventive medications, median (IQR) | 5 (4–6) | 2 (1–2) | < 0.001 | 4 (2–5) |
Medication overuse, no. (%) | 72 (49.3%) | 18 (28.5%) | 0.356 | 90 (43.1%) |
Chronic migraine, no. (%) | 94 (64.4%) | 23 (36.5%) | < 0.001 | 117 (56.0%) |
Disease duration, mean (SD), yr | 30.52 (12.41) | 19.60 (12.20) | < 0.001 | 27.22 (13.03) |
Comorbid depression, no. (%) | 51 (34.9%) | 14 (22.2%) | 0.069 | 65 (31.1%) |
Full starting dose (140 mg), no. (%) | 10 (6.8%) | 32 (50.8%) | < 0.001 | 42 (20.1%) |